NCT01606384View on ClinicalTrials.gov

Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Major Depressive Disorder
Interventions
DRUG

VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)

Pharmaceutical form: Capsule Route of administration: oral

DRUG

Placebo

Pharmaceutical form: Capsule Route of administration: Oral

Trial Locations (1)

Unknown

Sanofi-Aventis, Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01606384 - Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter